Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...